Kanglong Chemical (03759) announced interim results. Profit attributable to shareholders of 750 million yuan increased 7% year-on-year

According to the Zhitong Finance App, Kanglong Chemical (03759) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 7.595 billion yuan during the period, an increase of 17.9% over the previous year; profit attributable to owners of the parent company was 750 million yuan, an increase of 7% over the previous year; and the basic profit per share was 0.4138 yuan.

The company continues to deepen the customer-centered service concept, relies on a full-process integrated service platform, follows the highest international quality supervision standards, gives full play to the advantages of close collaboration between China, Britain and the US, and meets the diverse needs of global customers at different stages of R&D. In terms of strategic customer development, the company has dug deep into customer needs and achieved remarkable results. The customer business performance of large pharmaceutical companies is particularly outstanding. At the same time, the company continues to expand customer coverage and empower customers to develop new drugs with cutting-edge technology. While maintaining industry leadership in the field of small molecules, new molecular type projects have also achieved rapid development. For the Chinese market, the company actively pursues a market strategy that is more in line with the Chinese market. Along with the acceleration of the internationalization process of innovative drugs in China, the business of Chinese customers has achieved rapid growth. In the first half of 2026, along with the continuous expansion of the company's strategic customers and the continuous advancement of the CDMO service project pipeline, the company's new orders increased by more than 30% year-on-year. Based on new orders and business trends, the company expects revenue growth of 15% to 20% year-on-year for the full year of 2026.